Log In
BCIQ
Print this Print this
 

Openvas Co, olmesartan/hydrochlorothiazide (Benicar HCT)

  Manage Alerts
Collapse Summary General Information
Company Daiichi Sankyo Co. Ltd.
DescriptionA fixed dose combination of olmesartan and hydrochlorothiazide
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationHypertension
Indication DetailsTreat hypertension
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today